This study suggests that lumbar muscle quality can serve as a sensitive predictor of the therapeutic effects of PD‐1/PD‐L1 inhibitor monotherapy in patients with NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.